The antibiotic doxycycline can interrupt the formation of negative associations in the brain, new research from University College London and the University of Zurich suggests.
The study was a placebo-controlled, double-blind randomised controlled trial involving 76 healthy volunteers. In the first session, participants were given either doxycycline or a placebo and learned to associate a certain color with an electric shock.
A week later they were shown the colors again, accompanied by a loud sound but no shocks, and their fear responses were measured.
The response to fear was reduced 60% in volunteers who had doxycycline in the first session compared to those who had the placebo. This suggests that the fear memory was significantly suppressed by the drug. Other cognitive measures including sensory memory and attention were not affected.
Reducing Fear Response With Doxycycline
Doxycycline. Credit: Norm Copeland CC-BY
Lead author Professor Dominik Bach of the UCL Wellcome Centre for Neuroimaging, Max Planck UCL Centre for Computational Psychiatry and Ageing Research and University of Zurich Division of Clinical Psychiatry Research, explains:
“When we talk about reducing fear memory, we are not talking about deleting the memory of what actually happened. The participants may not forget that they received a shock when the screen was red, but they ‘forget’ to be instinctively scared when they next see a red screen. Learning to fear threats is an important ability for any organism, helping us to avoid dangers such as predators. Over-prediction of threat, however, can cause tremendous suffering and distress in anxiety disorders such as PTSD.”
Post-traumatic stress disorder (PTSD) is a term for a broad range of psychological symptoms that can develop after someone experiences or witnesses a traumatic event. PTSD is caused by an overactive fear memory, and the new research shows that doxycycline can reduce the fear memory response in healthy volunteers.
“We have demonstrated a proof-of-principle for an entirely new treatment strategy for PTSD,” explains Professor Bach. “The theory is based on the recent discovery that our brains need proteins outside nerve cells, called matrix enzymes, to form memories. Matrix enzymes are found throughout the body, and their over-activity is involved in certain immune diseases and cancers.
To treat such diseases, we already have clinically approved drugs that block these enzymes, including the antibiotic doxycycline, so we wanted to see if they could help to prevent fear memories from forming in the brain. Our results support this theory, opening up an exciting avenue of research that might help us to find treatments for PTSD.
Using drugs to prevent PTSD would be challenging, since in the real world we don’t know when a traumatic event is about to occur. However, there is growing evidence that people’s memories and associations can be changed after the event when they experience or imagine similar situations. This is called ‘reconsolidation’, and we now plan to test the effect of doxycycline on reconsolidation of fear memories. If this is successful, we would hope to apply the technique to more clinically realistic models of PTSD within a few years.”
The study was supported by the Swiss National Science Foundation and the University of Zurich.